SCHEMBL6563388

SCHEMBL6563388

CC(C)S(=O)(=O)NCCCc1ccc(CCNS(=O)(=O)C(C)C)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 3/20 0.69
GRIA1 P42261 3/20 0.57
POLB P06746 1/20 0.50
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
TSHR P16473 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CA5A P35218 1/20 0.42
CA14 Q9ULX7 1/20 0.42
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6562905 0.96 GRIA4 (0.63) GRIA4GRIA1POLBALDH1A1MEN1
SCHEMBL6565144 0.93 GRIA4 (0.77) GRIA4GRIA1ALDH1A1MEN1KMT2A
SCHEMBL5186027 0.85 GRIA1 (0.52) GRIA4GRIA1POLBALDH1A1MEN1
SCHEMBL6563273 0.84 GRIA4 (0.67) GRIA4GRIA1POLB
SCHEMBL5877603 0.84 GRIA4 (0.67) GRIA4GRIA1ALDH1A1MEN1KMT2A
SCHEMBL7166935 0.84 GRIA4 (0.66) GRIA4POLBALDH1A1CA12CA9
SCHEMBL6759420 0.83 GRIA4 (0.50) GRIA4GRIA1POLBALDH1A1LMNA
SCHEMBL7567023 0.83 GRIA4 (0.50) GRIA4GRIA1ALDH1A1MEN1KMT2A
SCHEMBL6762111 0.81 GRIA4 (0.63) GRIA4GRIA1POLBALDH1A1MEN1
SCHEMBL6766132 0.81 GRIA4 (0.48) GRIA4GRIA1POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 GRIA4 17/4885GRIA1 9/4885POLB 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.